Внимание! Сравните стоимость вашего курса на выздоровление с рынком цен в Индии.
Изучите личный опыт форумчан, чтобы избежать «помощи» посредников.
(Для доступа к разделу требуется регистрация на форуме)
Модераторы: VeraVEK, Vitek, Werwert, Модераторы
![:]80](./images/smilies/80.gif "M-m-m-m-m!"){kind=small}
Добро пожаловать в наш дружный коллектифф 
![:]82](./images/smilies/74.gif "млин"){kind=small}
Правильно сделали, что пошли на вторую теру! А вот теперь давай посмотрим на рекомендации дока, которые он дал YAVA55 при F4: соф+дак+асун+рибы на 24 нед или соф+дак+сим на 12 недель.WiNNER писал(а):По первому тройному КИ соф+дак+сим уже есть впечатляющие результаты. Из 40 циррозников 100% УВО при 12-недельном курсе.
Ну вообще-то есть разница)))сима-сима писал(а):Да и какая разница когда он был подключён? Важен результат .
Лана_ писал(а):А разве сим и асун одно и тоже ? Сим, как я понимаю, это сильный препарат,
поэтому и дорогой. А асун, малая доля от сима. Разъясните пожалуйста,
Мнение Бурневича на счет Асуна мне известно.Nessi писал(а):А вот теперь давай посмотрим на рекомендации дока, которые он дал YAVA55 при F4: соф+дак+асун+рибы на 24 нед или соф+дак+сим на 12 недель.
Этим сказано его отношение к эффективности асуна.
Оригинал здесь:2.6. Simeprevir
In November 2013, the FDA approved simeprevir (TMC-435), a macrocyclic PI with a once per day dosing regimen and antiviral activity against genotypes 1, 2, 4, 5, and 6 [29]. A 150 mg dose was approved in the US, but a lower 100 mg dose was approved in Japan. Like telaprevir, simeprevir was approved for use in combination with peg-interferon and ribavirin, but SVR rates were higher and incidence of adverse events was lower than in telaprevir triple therapy, although rash and photosensitivity are more common than with peg-interferon and ribavirin alone. Simeprevir also has the advantage of once-daily dosing, compared to telaprevir’s twice or three times daily dosing, and unlike telaprevir, it is not required to be ingested with a high-fat meal. Inhibition of the bilirubin transporter organic anion transporter protein B1 (OATP1B1) leads to elevation of serum bilirubin in some patients, but simeprevir is 1000 times less active against 20 human proteases than against the viral protease [21,30]. Simeprevir can also be given to liver transplant recipients without dose adjustments for cyclosporine or tacrolimus. In spite of these improvements, simeprevir is vulnerable to antiviral resistance (Q80, S122, R155, and D168) and should not be used in patients who failed to respond to prior PI therapy due to cross-resistance. SVR was also significantly reduced in genotype 1a patients in whom Q80K variants were present at baseline.
2.7. Asunaprevir (BMS-650032)
In July 2014, Japan approved asunaprevir for use in combination with the NS5A inhibitor daclatasvir, making it the first approved all-oral, interferon/ribavirin-free DAA therapy [31]. Another of the first generation second-wave PIs, asunaprevir has improved safety with once or twice daily oral administration and antiviral activity against genotypes 1, 4, 5, and 6. Although the barrier to resistance is higher than in first wave PIs, asunaprevir resistance has been reported for several variants: F43S, S122G/N/R, R155K, D168A/E/G/V/Y, and V170T. Although asunaprevir is being used successfully in Japan, due to differences in genotype frequencies between the two populations and faced with increasing competition from Gilead (Foster City, CA, US) and AbbVie (North Chicago, IL, US), Bristol-Myers Squibb (New York, NY, US) has withdrawn its application for asunaprevir in the US.
|
|
